Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (pulmonary edema) rich in neutrophils, and in the absence of clinical heart failure. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
Features include common findings: Pneumonia, Dyspnea, Respiratory distress, and Pulmonary infiltrates and others; and sometimes findings: Edema, Acute pancreatitis, Fever, and Hemoptysis and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 7 | Pneumonia, Dyspnea, Respiratory distress |
Biomarker and diagnostic research for acute lung injury has been reported in the published literature.
Phenotype severity distribution: 11 common features.
Estimated prevalence: 1-5 in 10,000 (Uncommon).
20 clinical trials registered, 3 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 1 PHASE4, 1 PHASE3, 4 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06513949](https://clinicaltrials.gov/study/NCT06513949) |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 3:03 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acute lung injury
Lab test results
2 |
Elevated CRP (inflammation marker) (elevated circulating c-reactive protein concentration), Increased circulating interleukin 6 concentration |
Digestive system | 1 | Acute pancreatitis |
Metabolism | 1 | Fever |
Brain and nerves | 1 | Addictive alcohol use |
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients |
PHASE2 |
Implicit Bioscience |
RECRUITING |
[NCT05002478](https://clinicaltrials.gov/study/NCT05002478) | Infants With Severe Acute Respiratory Distress Syndrome: The Prone Trial | NA | Medical University of Vienna | RECRUITING |
[NCT07613099](https://clinicaltrials.gov/study/NCT07613099) | Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging | PHASE3 | National Heart, Lung, and Blood Institute (NHLBI) | RECRUITING |
358 publications have been identified in PubMed for acute lung injury. Kisho has analyzed 248 by research type. Research spans Basic Science / Preclinical (71%), Review / Meta-Analysis (21%), and Gene Therapy / Novel Therapeutics (6%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 176 | 71% |
Research summaries | 52 | 21% |
New treatment approaches | 16 | 6% |
Testing and diagnosis research | 2 | 1% |
Disease patterns and progression | 2 | 1% |
Ma J (2026). [PMID: 41478107](https://pubmed.ncbi.nlm.nih.gov/41478107/). *Biomaterials*. [Gene Therapy / Novel Therapeutics]
Lai X (2026). [PMID: 42051508](https://pubmed.ncbi.nlm.nih.gov/42051508/). *Front Immunol*. [Review / Meta-Analysis]
Liu S (2026). [PMID: 41105248](https://pubmed.ncbi.nlm.nih.gov/41105248/). *Naunyn Schmiedebergs Arch Pharmacol*. [Basic Science / Preclinical]
Xiao F (2026). [PMID: 41518848](https://pubmed.ncbi.nlm.nih.gov/41518848/). *Redox Biol*. [Basic Science / Preclinical]
Yang SY (2026). [PMID: 40912485](https://pubmed.ncbi.nlm.nih.gov/40912485/). *J Ethnopharmacol*. [Basic Science / Preclinical]
Babu MA (2026). [PMID: 41456737](https://pubmed.ncbi.nlm.nih.gov/41456737/). *Clin Chim Acta*. [Review / Meta-Analysis]
Ma Y (2026). [PMID: 40930288](https://pubmed.ncbi.nlm.nih.gov/40930288/). *J Ethnopharmacol*. [Basic Science / Preclinical]
Zhu Y (2026). [PMID: 40460939](https://pubmed.ncbi.nlm.nih.gov/40460939/). *J Adv Res*. [Basic Science / Preclinical]
Wang J (2026). [PMID: 41903585](https://pubmed.ncbi.nlm.nih.gov/41903585/). *J Ethnopharmacol*. [Basic Science / Preclinical]
Chen S (2026). [PMID: 41761421](https://pubmed.ncbi.nlm.nih.gov/41761421/). *Antioxid Redox Signal*. [Basic Science / Preclinical]
AI-curated news mentioning acute lung injury
Updated Aug 18, 2026
Research reveals that inhalable carrier-free self-assembled nanoaggregates of leonurine and ursolic acid can improve outcomes in acute lung injury by targeting the TLR4/MyD88-NET signaling pathway. This study contributes to the understanding of potential therapeutic strategies for lung injuries.
Research reveals that an intranasal nanoparticle targeting the ORAI1 protein in neutrophils can reduce acute lung injury associated with pancreatitis and sepsis. This discovery may open new avenues for therapeutic interventions in these conditions.
A recent case-crossover study published in PubMed examines the relationship between direct oral anticoagulant consumption and the risk of acute interstitial lung diseases. The findings contribute to understanding potential risks associated with anticoagulant therapies.